Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geissler

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanesThomas H Graham, Wensheng Liu, Andreas Verras, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2015
Development of a novel class of potent and selective FIXa inhibitorsTing Zhang, Patrick Andre, Thomas J Bateman, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.
European Child & Adolescent Psychiatry|January 4, 2020
Correction to: Does helping mothers in multigenerational ADHD also help children in the long run? 2‑year follow‑up from baseline of the AIMAC randomized controlled multicentre trialJulia M Geissler, Timo D Vloet, Nora Strom, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.
European Child & Adolescent Psychiatry|December 7, 2019
Does helping mothers in multigenerational ADHD also help children in the long run? 2-year follow-up from baseline of the AIMAC randomized controlled multicentre trialJulia M Geissler, Timo D Vloet, Nora Strom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanesThomas H Graham, Wensheng Liu, Andreas Verras, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2015
Development of a novel class of potent and selective FIXa inhibitorsTing Zhang, Patrick Andre, Thomas J Bateman, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2012
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluationThomas H Graham, Wensheng Liu, Andreas Verras, et al.
European Child & Adolescent Psychiatry|January 4, 2020
Correction to: Does helping mothers in multigenerational ADHD also help children in the long run? 2‑year follow‑up from baseline of the AIMAC randomized controlled multicentre trialJulia M Geissler, Timo D Vloet, Nora Strom, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitorsThomas H Graham, Hong C Shen, Wensheng Liu, et al.
European Child & Adolescent Psychiatry|December 7, 2019
Does helping mothers in multigenerational ADHD also help children in the long run? 2-year follow-up from baseline of the AIMAC randomized controlled multicentre trialJulia M Geissler, Timo D Vloet, Nora Strom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pageof 13